Executive SummaryJohnson & Johnson is providing $70 mil. to Scripps Clinic & Research Foundation under a 10-year research agreement. The funding will be used to support biomedical projects at Scripps' Research Institute, J&J said. J&J will have right of first refusal to develop and market any discoveries from the research.
You may also be interested in...
The US Senate overwhelmingly approved a bill on 16 January to implement the US-Mexico-Canada agreement, which includes a new chapter on the handling of medical devices supported by the medtech industry.
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.